Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Syros Pharmaceuticals Inc SYRS

Healthcare Biotechnology
Syros Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing new standards of care for the frontline treatment of patients with hematologic malignancies. The Company is advancing Tamibarotene, a selective retinoic acid receptor alpha (RARa), agonist for which the Company is conducting SELECT-MDS-1, a Phase III clinical trial evaluating tamibarotene in... see more

Recent & Breaking News (NDAQ:SYRS)

Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire July 5, 2023

Syros to Present at Sidoti June 2023 Virtual Small-Cap Conference

Business Wire June 8, 2023

Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire June 1, 2023

Syros Presents Data from Phase 1/1b Clinical Trial of SY-5609 in Advanced Solid Tumors at ASCO Annual Meeting

Business Wire May 25, 2023

Syros Reports First Quarter 2023 Financial Results and Provides a Corporate Update

Business Wire May 10, 2023

Syros to Present at JMP Securities 2023 Life Sciences Conference

Business Wire May 9, 2023

Syros to Report First Quarter 2023 Financial Results on Wednesday, May 10, 2023

Business Wire May 3, 2023

Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire May 2, 2023

Syros Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate Update

Business Wire March 2, 2023

Syros to Participate in Upcoming Investor Conferences in March

Business Wire February 28, 2023

Syros to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 2, 2023

Business Wire February 23, 2023

Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Higher-Risk Myelodysplastic Syndrome

Business Wire January 26, 2023

Syros Announces Clinical Updates and 2023 Strategic Priorities

Business Wire January 9, 2023

Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire December 23, 2022

Syros Pharmaceuticals Announces Publication in Blood Advances Demonstrating the Potential of Tamibarotene in Patients with RARA Gene Overexpression, Supporting Ongoing Clinical Development in AML and MDS

Business Wire December 12, 2022

Syros Presents Safety Lead-in Data from SELECT-AML-1 Trial Evaluating Tamibarotene in Combination with Venetoclax and Azacitidine and Announces Plans to Initiate Randomized Portion of Phase 2 Trial

Business Wire December 10, 2022

Syros to Host Virtual Event to Discuss Initial SELECT-AML-1 Data and Unmet Need in Newly Diagnosed Unfit Acute Myeloid Leukemia on December 10

Business Wire December 5, 2022

Syros to Participate at Piper Sandler 34th Annual Healthcare Conference

Business Wire November 22, 2022

Syros Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides a Corporate Update

Business Wire November 14, 2022

Syros to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022

Business Wire November 7, 2022